Search company, investor...
Atrium Innovations company logo

Atrium Innovations

atrium-innovations.com

Founded Year

1999

Stage

Acquired | Acquired

Total Raised

$2M

Valuation

$0000 

Revenue

$0000 

About Atrium Innovations

Atrium Innovations specializes in the development, manufacturing, and commercialization of science-based natural health products which are distributed in more than 35 countries. The company's brands include Wobenzym, Garden of Life, Trophic, and more.

Headquarters Location

Place Alexis Nihon, Tower 2, 24th Floor 3500 de Maisonneuve Boulevard West, Suite 2405

Montreal, Quebec, H3G 3C1,

Canada

514-205-6240

Missing: Atrium Innovations's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Atrium Innovations's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Atrium Innovations

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Atrium Innovations is included in 1 Expert Collection, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

Latest Atrium Innovations News

Nestle buys vitamin brands from KKR for $5.75 billion

Apr 30, 2021

3 min read . Updated: 30 Apr 2021, 03:33 PM IST Bloomberg Chief Executive Officer Mark Schneider dove into the field of vitamins and supplements in his first year as CEO in 2017 with the $2.3 billion acquisition of Atrium Innovations Inc. Share Via Nestle SA agreed to buy vitamin maker Bountiful Co. for $5.75 billion, becoming a world leader in the field of minerals and supplements as the pandemic boosts demand for pills for health-conscious consumers. Nestle Health Science Chief Executive Officer Greg Behar said the purchase -- from private equity firms KKR & Co. and Carlyle -- should double e-commerce revenue from supplements to about $1 billion this year. 1 min read . 02:05 PM IST Chief Executive Officer Mark Schneider dove into the field of vitamins and supplements in his first year as CEO in 2017 with the $2.3 billion acquisition of Atrium Innovations Inc. He has focused on developing larger brands in the competitive, fragmented segment, seeing a market in high-spending health-conscious consumers. “The bolt-on acquisition fits well with Nestle’s strategy to further expand in the highly attractive and globally growing category of specialized nutrition," wrote Patrik Schwendimann, an analyst at Zuercher Kantonalbank. He said the price, equal to 16.8 times earnings before interest, tax, depreciation and amortization, seems fair. Schneider’s strategy has delivered, with Nestle recently reporting sales growth at double the pace analysts predicted. About 91% of people taking supplements have increased consumption during the pandemic to boost their immune system, Behar said. Nestle Health Science’s revenue rose almost 10% in the first quarter on an adjusted basis. Shares Gain Nestle shares have gained more than 70% since Schneider became CEO, and the company is worth more than $300 billion. The stock was little changed in Zurich Friday morning. The company plans to offer more services that recommend specific nutrients to individual consumers, similar to the business of Persona, a personalized vitamin company that it bought in late 2019. 2 min read . 02:38 PM IST Nestle said it expects the transaction to close in the second half and weigh on profitability this year due to one-time integration costs. What Bloomberg Intelligence Says: Nestle’s $5.75 billion acquisition -- at a price of 3.1x sales and 16.8x Ebitda -- of brands including Natures Bounty and Solgar from The Bountiful Company fits its specialist nutrition and wellness focus and adds another lever to growth once integrated into the business. The deal increases Nestle’s net debt-to-Ebitda ratio to about 2x from 1.7x, so it won’t affect its ability to either acquire further assets, or buy back shares. -- Duncan Fox, BI consumer-goods analyst Nestle’s Specialist-Nutrition Agenda Gets Bountiful Kick: React KKR had been planning an initial public offering valuing Bountiful at more than $6 billion, Bloomberg News reported in January. Schneider has made more than 50 deals since taking over at the helm of the Swiss firm, and has said Nestle plans more acquisitions in the coming years to balance out the numerous divestments made over the past years including U.S. bottled-water businesses. Bountiful sells a wide range of vitamins that are available in retail chains such as Walmart, CVS and Rite Aid. The pandemic has boosted demand for products that are advertised as helping consumers’ health and immune systems. Evercore, Morgan Stanley and JPMorgan advised KKR. Simpson Thacher & Bartlett LLP was its legal counsel. Share Via

Atrium Innovations Frequently Asked Questions (FAQ)

  • When was Atrium Innovations founded?

    Atrium Innovations was founded in 1999.

  • Where is Atrium Innovations's headquarters?

    Atrium Innovations's headquarters is located at Place Alexis Nihon, Tower 2, 24th Floor, Montreal.

  • What is Atrium Innovations's latest funding round?

    Atrium Innovations's latest funding round is Acquired.

  • How much did Atrium Innovations raise?

    Atrium Innovations raised a total of $2M.

  • Who are the investors of Atrium Innovations?

    Investors of Atrium Innovations include Nestle, Fonds de Solidarite FTQ, Permira and Caisse de depot et placement du Quebec.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.